DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $798,711 | +8.0% | 3,219 | +4.5% | 0.18% | +15.6% |
| Q2 2023 | $739,515 | -4.8% | 3,081 | -0.0% | 0.15% | -3.1% |
| Q1 2023 | $776,866 | +95221.0% | 3,082 | +0.3% | 0.16% | -9.1% |
| Q4 2022 | $815 | -99.9% | 3,072 | +14.9% | 0.18% | +3.6% |
| Q3 2022 | $690,000 | -8.4% | 2,673 | -10.0% | 0.17% | -6.1% |
| Q2 2022 | $753,000 | -7.5% | 2,970 | +7.1% | 0.18% | -12.6% |
| Q1 2022 | $814,000 | -44.5% | 2,774 | -37.8% | 0.21% | -44.0% |
| Q4 2021 | $1,467,000 | +8.3% | 4,458 | +0.2% | 0.37% | -2.9% |
| Q3 2021 | $1,355,000 | +10.7% | 4,451 | -2.4% | 0.38% | +12.5% |
| Q2 2021 | $1,224,000 | -16.9% | 4,562 | -30.3% | 0.34% | -20.9% |
| Q1 2021 | $1,473,000 | +56.0% | 6,544 | +53.9% | 0.43% | +46.9% |
| Q4 2020 | $944,000 | +12.9% | 4,251 | +9.5% | 0.29% | -7.6% |
| Q3 2020 | $836,000 | +30.2% | 3,882 | +6.9% | 0.31% | +46.0% |
| Q2 2020 | $642,000 | +29.7% | 3,632 | +1.7% | 0.22% | +4.4% |
| Q1 2020 | $495,000 | -8.3% | 3,573 | +1.6% | 0.21% | +12.0% |
| Q4 2019 | $540,000 | +11.3% | 3,517 | +4.8% | 0.18% | -1.6% |
| Q3 2019 | $485,000 | +10.5% | 3,356 | +9.3% | 0.19% | +12.7% |
| Q2 2019 | $439,000 | +9.2% | 3,070 | +0.8% | 0.17% | +4.4% |
| Q1 2019 | $402,000 | +24.5% | 3,047 | -2.6% | 0.16% | +30.3% |
| Q4 2018 | $323,000 | -16.1% | 3,128 | -11.7% | 0.12% | -17.0% |
| Q3 2018 | $385,000 | +10.0% | 3,542 | 0.0% | 0.15% | -2.6% |
| Q2 2018 | $350,000 | +0.9% | 3,542 | 0.0% | 0.15% | -2.6% |
| Q1 2018 | $347,000 | +5.5% | 3,542 | 0.0% | 0.16% | +13.1% |
| Q4 2017 | $329,000 | +8.2% | 3,542 | +0.1% | 0.14% | +3.8% |
| Q3 2017 | $304,000 | -14.8% | 3,538 | -16.4% | 0.13% | -19.0% |
| Q2 2017 | $357,000 | +9.5% | 4,233 | +11.2% | 0.16% | +1.2% |
| Q1 2017 | $326,000 | +10.1% | 3,807 | +0.2% | 0.16% | +3.9% |
| Q4 2016 | $296,000 | -92.2% | 3,801 | +1175.5% | 0.16% | +18.3% |
| Q3 2016 | $3,796,000 | +891.1% | 298 | -92.1% | 0.13% | -37.9% |
| Q2 2016 | $383,000 | +6.4% | 3,796 | 0.0% | 0.21% | +3.9% |
| Q1 2016 | $360,000 | +13.2% | 3,796 | +10.9% | 0.20% | +27.7% |
| Q4 2015 | $318,000 | -3.0% | 3,423 | -11.0% | 0.16% | -18.9% |
| Q3 2015 | $328,000 | -0.3% | 3,846 | 0.0% | 0.20% | -6.2% |
| Q2 2015 | $329,000 | – | 3,846 | – | 0.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |